Trials begin on pill that could control cancer
Friday 19 May 1995
Trials with patients have just started on a cancer "pill" that is designed to stop tumours growing and prevent the spread of disease.
While its inventor, British Biotech of Oxford, stresses that the project is at a very early stage, it says the drug, a chemical compound called BB-2516, has exciting potential.
The trials started last month in Britain and the US. So far, only 10 patients with either colon, ovarian, prostate or pancreatic cancer have been enrolled. For a month they will take two capsules a day. All are patients with secondary cancers for whom no standard treatment is available.
More patients will be recruited into the programme this year, to a total of 30 in each group. Additionally, Canadian authorities have given permission for a similar trial with patients with the skin cancer, melanoma.
Keith McCullagh, chief executive of British Biotech, said: "If you can take a pill every day for the rest of your life that keeps the cancer under control, it will transform people's expectations of cancer."
However, he warned against raising expectations too high at this stage, despite encouraging trials in animals.
He said: "Until we complete these preliminary human trials, we can't say anything positive."
The drug blocks the actions of enzymes called matrix metalloproteinases. In cancer tumours they are overproduced. By disrupting their activity, BB-2516 should stop cancer spreading and prevent tumours from establishing their own blood supply, which they need to grow. It is designed to treat solid cancers, not leukaemias.
Trials in mice were successful and last year the safety of the drug in humans was tested on 30 healthy volunteers.
They took the drug for a day, then for a week without side-effects. The scientists were also able to establish that at different doses, enough of the drug survives in the bloodstream to be effective.
A spokeswoman for British Biotech said the company believed it was the first in the world to be at the clinical trials stage with this class of drug.
"It is very early days, but it is exciting," she said.
British Biotech was founded 9 years ago, and originally employed just 10 scientists. The workforce has since expanded to more than 300.
- 1 Three-year-old ultra-Orthodox Jewish children told 'the non-Jews' are 'evil' in worksheet produced by London school
- 2 Moscow voted the world's unfriendliest city
- 3 The excuses your boss is most likely to believe when you call in sick
- 4 I'm pansexual – here are the five biggest misconceptions about my sexuality
- 5 More than 11,000 Icelanders offer to house Syrian refugees to help European crisis
The one chart that shows how George Osborne is almost certainly going to be our next Prime Minister
The excuses your boss is most likely to believe when you call in sick
Bono's group has made more money from Facebook investment than from all his music
Three-year-old ultra-Orthodox Jewish children told 'the non-Jews' are 'evil' in worksheet produced by London school
Wikipedia rocked by 'rogue editors' blackmail scam targeting small businesses and celebrities
Climate change: 2015 will be the hottest year on record 'by a mile', experts say
Jeremy Corbyn calls Osama bin Laden's killing a 'tragedy' - but was it taken out of context?
If these extraordinarily powerful images of a dead Syrian child washed up on a beach don’t change Europe’s attitude to refugees, what will?
If you're not already angry about the refugee crisis, here's a history lesson to remind you why you really should be
Tony Blair attacks Jeremy Corbyn's 'Alice In Wonderland' politics
Theresa May says migrants should be banned from entering the UK unless they have jobs lined up
£40000 - £42000 per annum: Recruitment Genius: This is an exciting opportunity...
£35000 - £40000 per annum: Recruitment Genius: This IT support company has a n...
Negotiable: Recruitment Genius: A works engineer is required in a progressive ...
£21000 - £25000 per annum: Recruitment Genius: Our client is seeking someone w...